A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Exendin-(9,39) has been shown to have effects on beta-cell function, and after gastric
bypass, to accelerate gastrointestinal transit. - infused at rates of 300pmol/kg/min. Given
that gastrointestinal transit is typically delayed by Glucagon-Like Peptide-1 (GLP-1) and
also that this hormone causes decreased food intake through increased satiation, it is
reasonable to expect an effect of Exendin-9,39 on appetite. This may help explain the effects
of gastric bypass on food intake. To examine the effect of Exendin on food intake we propose
a dose-response study to determine whether the compound has effects in a dose-dependent
fashion. We will examine the presence of gastrointestinal symptoms as well as food intake in
the immediate aftermath of a test meal and the subsequent hours.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)